Damon Michaels, chief operating officer of emerging biotech and life sciences company Mydecine sat down with The Dales Report last week to discuss the company’s latest activity.
“We’re dedicated to taking a holistic approach toward making alternative medicine traditional medicine,” Michaels said in the interview.
Mydecine intends to do that by focusing heavily on drug development, as well as developing novel delivery systems. Michaels said the company will soon be conducting clinical trials “for the many safe and effective active and medicinal compounds found within fungi or mushrooms,” while CEO Jason Bartch announced recently that Mydecine is cultivating psilocybin mushrooms to be used in a phase two clinical trial for post-traumatic stress disorder.
Additionally, Michaels said the company is the first to establish a certified CGMP global supply chain for psychedelic medicinal mushrooms, and announced last week that it had completed the first-ever international export of psilocybin mushrooms out of Jamaica.